Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.
Results from NASA’s landmark Twins Study reveals some interesting, surprising and reassuring data.
Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.
Researchers with the Icahn School of Medicine at Mount Sinai in New York have had promising results with a cancer vaccine.
Taking caffeine before exercise could improve performance during a broad range of exercise tasks, according to a new review of past research.
A new report published by researchers at Northwestern University offers the possibility of an early diagnostic test for Alzheimer’s disease – via an eye test.
Blood pressure and stroke risk rise steadily the more alcohol people drink, and previous claims that one or two drinks a day might protect against stroke are not true, according to a genetic study.
Scientists at the National Institutes of Health (NIH) launched a trial to examine a potential universal flu vaccine candidate, known as H1ssF_3928.
ViiV Healthcare presented three-year data from the SWORD 1 and 2 clinical trials in HIV.
Astellas Pharma’s blood cancer drug Xospata continues to show impressive results in the acute myeloid leukemia setting.